TNF-alpha Production by Peripheral Blood Monocytes in Multiple Sclerosis Patients and Healthy Controls

References

• Batocchi AP, Rotondi M, Caggiula G, et al. (2003). Leptin as a marker of multiple sclerosis activity in patients treated with interferon-beta. J Neuroimmunol, 139, 150–4
   PubMed Web of Science ®Google Scholar
• Begum F, Zhu W, Cortes C, et al. (2013). Elevation of tumor necrosis factor alpha in dorsal root ganglia and spinal cord is associated with neuroimmune modulation of pain in an animal model of multiple sclerosis. J Neuroimmune Pharmacol, 8, 677–90
   PubMed Web of Science ®Google Scholar
• Carrieri PB, Provitera V, Rosa TD, et al. (1998). Profile of cerebrospinal fluid and serum cytokines in patients with relapsing-remitting multiple sclerosis. A correlation with clinical activity. Immunopharmacol Immunotoxicol, 20, 373–82
   PubMed Web of Science ®Google Scholar
• Codarri L, Fontana A, Becher B, et al. (2010). Cytokine networks in multiple sclerosis: Lost in translation. Curr Opin Neurol, 23, 205–11
   PubMed Web of Science ®Google Scholar
• Faustman D, Davis M. (2010). TNF receptor 2 pathway: Drug target for autoimmune diseases. Nat Rev Drug Discov, 9, 482–93
   PubMed Web of Science ®Google Scholar
• Hasheminia SJ, Zarkesh-Esfahani SH, Toluei S, et al. (2014). Toll like receptor 2 and 4 expression in peripheral blood mononuclear cells of multiple sclerosis patients. Iran J Immunol, 11, 74–83
   PubMed Web of Science ®Google Scholar
• Hohnoki K, Inoue A, Koh CS, et al. (1998). Elevated serum levels of IFN- γ, IL-4 and TNF- α/unelevated serum levels of IL-10 in patients with demyelinating diseases during the acute stage. J Neuroimmunol, 87, 27–32
   PubMed Web of Science ®Google Scholar
• Holmoy T. (2007). Immunopathogenesis of multiple sclerosis: Concepts and controversies. Acta Neurol Scand, 87, 39–45
   Web of Science ®Google Scholar
• Imamura K, Suzumura A, Hayashi F, et al. (1993). Cytokine production by peripheral blood monocytes/macrophages in multiple sclerosis patients. Acta Neurologica Scandinavica, 87, 281–5
   PubMed Web of Science ®Google Scholar
• Imitola J, Chitnis T, Khoury SJ, et al. (2005). Cytokines in multiple sclerosis: From bench to bedside. Pharmacol Therapeut, 106, 163–77
   PubMed Web of Science ®Google Scholar
• Kallaur AP, Oliveira SR, Delicato de Almeida ER, et al. (2013). Cytokine profile in relapsing-remitting multiple sclerosis patients and the association between progression and activity of the disease. Mol Med Rep, 7, 1010–20
   PubMed Web of Science ®Google Scholar
• Katsavos S, Anagnostouli M. (2013). Biomarkers in multiple sclerosis: An up-to-date overview. Multiple Sclerosis International, 2013, 1–20. ID 340508
   Google Scholar
• Kouwenhoven M, Teleshova N, Özenci V, et al. (2001). Monocytes in multiple sclerosis: Phenotype and cytokine profile. J Neuroimmunol, 112, 197–205
   PubMed Web of Science ®Google Scholar
• Lam QL, Lu L. (2007). Role of leptin in immunity. Cell Mol Immuno, l4, 1–13
   Google Scholar
• Leung JC, Chan LY, Lam MF, et al. (2012). The role of leptin and its short-form receptor in inflammation in db/db mice infused with peritoneal dialysis fluid. Nephrol Dialysis Transplant, 27, 3119–29
   PubMed Web of Science ®Google Scholar
• Lindquist S, Hassinger S, Lindquist JA, et al. (2011). The balance of pro-inflammatory and trophic factors in multiple sclerosis patients: Effects of acute relapse and immunomodulatory treatment. Mult Scler J, 17, 851–66
   PubMed Web of Science ®Google Scholar
• Martins TB, Rose JW, Jaskowski TD, et al. (2011). Analysis of proinflammatory and anti-inflammatory cytokine serum concentrations in patients with multiple sclerosis by using a multiplexed immunoassay. Am J Clin Pathol, 136, 696–704
   PubMed Web of Science ®Google Scholar
• Mellergård J, Edström M, Vrethem M, et al. (2010). Natalizumab treatment in multiple sclerosis: Marked decline of chemokines and cytokines in cerebrospinal fluid. Mult Scler, 16, 208–17
   PubMed Web of Science ®Google Scholar
• Musabak U, Demirkaya S, Genç G, et al. (2010). Serum adiponectin, TNF-α, IL-12p70, and IL-13 levels in multiple sclerosis and the effects of different therapy regimens. Neuroimmunomodulation, 18, 57–66
   PubMed Web of Science ®Google Scholar
• Özenci V, Kouwenhoven M, Link H, et al. (2002). Cytokines in multiple sclerosis: Methodological aspects and pathogenic implications. Mult Scler, 8, 396–404
   PubMed Web of Science ®Google Scholar
• Patanella AK, Zinno M, Quaranta D, et al. (2010). Correlations between peripheral blood mononuclear cell production of BDNF, TNF-alpha, IL-6, IL-10 and cognitive performances in multiple sclerosis patients. J Neurosci Res, 88, 1106–12
   PubMed Web of Science ®Google Scholar
• Petrescu F, Voican SC, Silosi I, et al. (2010). Tumor necrosis factor-α serum levels in healthy smokers and nonsmokers. Int J Chronic Obstruct Pulmonary Dis, 5, 217–22
   PubMedGoogle Scholar
• Re F, Strominger JL. (2001). Toll-like receptor 2 (TLR2) and TLR4 differentially activate human dendritic cells. J Biol Chem, 276, 37692–9
   PubMed Web of Science ®Google Scholar
• Reale M, de Angelis F, di Nicola M, et al. (2012). Relation between pro-inflammatory cytokines and acetylcholine levels in relapsing-remitting multiple sclerosis patients. Int J Mol Sci, 13, 12656–64
   PubMed Web of Science ®Google Scholar
• Roses RE, Xu S, Xu M, et al. (2008). Differential production of IL-23 and IL-12 by myeloid-derived dendritic cells in response to TLR agonists. J Immunol, 181, 5120–7
   PubMed Web of Science ®Google Scholar
• Srivastava P, Mujtaba MA, Singhal M, et al. (2012). Gene and cytokines expression of multiple sclerosis and its therapeutic regimen: A systemic review. Int J Drug Dev Res, 4, 55–66
   Google Scholar
• Stepien A, Chalimoniuk M, Lubina-Dąbrowska N, et al. (2013). Effects of Interferon β-1a and Interferon β-1b monotherapies on selected serum cytokines and nitrite levels in patients with relapsing-remitting multiple sclerosis: A 3-year longitudinal study. Neuroimmunomodulation, 20, 213–22
   PubMed Web of Science ®Google Scholar
• van der Bruggen T, Nijenhuis S, van Raaij E, et al. (1999). Lipopolysaccharide-induced tumor necrosis factor alpha production by human monocytes involves the raf-1/MEK1-MEK2/ERK1-ERK2 pathway. Infect Immunity, 67, 3824–9
   PubMed Web of Science ®Google Scholar
• Vladic A, Horvat G, Vukadin S, et al. (2002). Cerebrospinal fluid and serum protein levels of tumour necrosis factor-alpha (TNF-α), interleukin-6 (IL-6) and soluble interleukin-6 receptor (sIL-6R gp80) in multiple sclerosis patients. Cytokine, 20, 86–9
   PubMed Web of Science ®Google Scholar
• Yadav, AR, Deo N. (2013). Influence of leptin on immunity. Curr Immunol Rev, 9, 23–30
   Google Scholar
• Zarkesh-Esfahani, H, Pockley G, Metcalfe RA, et al. (2001). High-dose leptin activates human leukocytes via receptor expression on monocytes. J Immunol, 167, 4593–9
   PubMed Web of Science ®Google Scholar
• Zielinski, CC, Budinsky AC, Wagner TMU, et al. (2003). Defect of tumour necrosis factor-α (TNF-α) production and TNF-α-induced ICAM-1–expression in BRCA1 mutations carriers. Breast Cancer Res Treat, 81, 99–105
   PubMed Web of Science ®Google Scholar